Merck

Last updated January 31, 2026

124

Innovation Areas

5,362

Inventors

Collaborations

Phthalazine and indazole scaffold inhibitors: MerckRecent Research Landscape

Uncontrolled NLRP3 inflammasome activation drives chronic inflammatory tissue damage, which is mitigated through the precise structural modification of phthalazine and indazole heterocyclic cores. These specific molecular scaffolds provide the necessary binding affinity to inhibit protein signaling and prevent systemic inflammation.

What technical problems is Merck addressing in Phthalazine and indazole scaffold inhibitors?

Aberrant kinase signaling

(24)evidences

Necroptosis and integrated stress response dysregulation lead to systemic tissue damage. Preventing these pathological pathways mitigates chronic inflammatory and neurodegenerative disease progression.

Aberrant kinase signaling toxicity

(5)evidences

Uncontrolled signaling through BTK and IRAK pathways drives chronic inflammatory and autoimmune pathologies. Inhibiting these specific nodes prevents systemic immune dysregulation.